| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Executive Officer
4 companies
Friedman Paul A is a Director at PRLD, with reported holdings spanning 4 companies. Recent filings cover 2 purchases and 107 sales. Those positions are worth an estimated $96.0M at current prices.
Our model assigns Friedman Paul A a below-average insider score of 36/100, based on 12 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -42.5%.
Friedman Paul A's largest disclosed position is in MDGL as Director, worth about $96.0M. The recent filings there lean toward selling, a net 421,382 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 9, 2026 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 24,520 | $522.39 | $12,808,956.93 | -11.6% | +2.0% | - | |
| Jan 9, 2026 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 280 | $551.24 | $154,347.59 | -0.1% | +2.0% | - | |
| Dec 10, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 24,800 | $552.18 | $13,694,157.83 | -11.7% | -21.7% | - | |
| Aug 13, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 130,809 | $370.29 | $48,437,036.39 | -41.1% | +45.0% | +35.9% | |
| Aug 12, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 46,808 | $355.31 | $16,631,386.12 | -20.0% | +38.1% | +49.4% | |
| Jul 18, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 1,400 | $350.03 | $490,043.96 | -0.7% | +32.3% | +65.6% | |
| Jul 17, 2025 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 28,876 | $353.19 | $10,198,844.04 | -13.4% | +24.3% | +58.7% | |
| Apr 8, 2024 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 26,270 | $246.19 | $6,467,490.86 | -12.4% | +16.9% | +21.8% | |
| Apr 5, 2024 | MDGL Madrigal Pharmaceuticals, Inc. | Director | Sale+OE10b5-1 | 73,730 | $243.93 | $17,984,804.49 | -28.4% | +13.8% | +29.4% | |
| Aug 6, 2019 | INCY Incyte Corp | Director | Sale+OE | 100,000 | $82.69 | $8,268,765.86 | -28.1% | - | - |